Autoimmune Monoclonal Antibody Market Size Forecasted To Achieve 98.81 Billion By 2029 With Steady Growth

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What Is the Autoimmune Monoclonal Antibody Market Size and Projected Growth Rate?
Recent years have seen robust growth in the autoimmune monoclonal antibody market. Currently valued at $65.83 billion in 2024, it's projected to expand to $71.71 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.7%. This marked progression in the historical period is due to factors such as the increasing occurrence of autoimmune diseases, enhanced use of biologics in treatment, growing awareness about targeted therapies, early sanctioning of monoclonal antibody drugs, and broader healthcare access in economically advanced nations.

Anticipated to experience robust growth in the coming years, the autoimmune monoclonal antibody market is forecasted to reach $98.81 billion by 2029, with a compound annual growth rate (CAGR) of 8.4%. The expansion during this estimated timeframe can be linked to a growing demand for custom medicine, augmented uptake of biosimilars, broad-ranging clinical trials in autoimmune therapy, an escalating geriatric population, and the increasing occurrence of chronic immune disorders. The forecast period is also marked by key trends such as improvement in antibody engineering, progress in bispecific antibodies, escalating utilization of artificial intelligence in drug discovery, application of genomics in treatment strategies, and new drug delivery systems.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/customise?id=24162&type=smp

What Are the Major Segments in the Autoimmune Monoclonal Antibody Market?
The autoimmune monoclonal antibody market covered in this report is segmented -

1) By Type: Immunoglobulin G Monoclonal Antibodies, Immunoglobulin M Monoclonal Antibodies, Chimeric Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Route Of Administration: Subcutaneous, Intravenous, Intramuscular
3) By Application: Rheumatoid Arthritis, Multiple Sclerosis, Systemic Lupus Erythematosus, Psoriasis, Inflammatory Bowel Disease
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Outpatient Clinics, Homecare Settings, Research Institutions

Subsegments:
1) By Immunoglobulin G (IgG) Monoclonal Antibodies: Immunoglobulin G1 (IgG1), Immunoglobulin G2 (IgG2), Immunoglobulin G3 (IgG3), Immunoglobulin G4 (IgG4)
2) By Immunoglobulin M (IgM) Monoclonal Antibodies: Pentameric Immunoglobulin M (IgM), Hexameric Immunoglobulin M (IgM)
3) By Chimeric Monoclonal Antibodies: Murine Variable Region + Human Constant Region, Humanized Variable Region + Murine Constant Region
4) By Fully Human Monoclonal Antibodies: Phage Display-Derived, Transgenic Mouse-Derived, Fully Human Hybridoma-Derived

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24162&type=smp

What Are The Driving Autoimmune Monoclonal Antibody Market Evolution?
The surge in demand for biologics is poised to spur the expansion of the autoimmune monoclonal antibody market in the future. Biologics, which are medical products derived from living beings or their components, are utilized in the prevention, diagnosis, and treatment of diseases. The rising popularity of biologics is mainly due to their demonstrated efficiency in treating complex ailments such as cancer, autoimmune disorders, and genetic conditions, where conventional therapies often fall short. Autoimmune monoclonal antibody bolsters biologic therapies since they offer targeted immune modulation, making them beneficial for controlling hyperactive immune reactions. These antibodies, by providing pinpoint treatment, reduces the requirement for wide-scale immunosuppressants, hence, enhancing patient results while reducing adverse effects. For example, according to a report released in June 2024 by Cardinal Health Inc., a US-based healthcare provider, 40 biosimilar products received FDA approval in 2023, with 25 of them being commercially available in the US market. This is a significant increase from the 33 biosimilar products recorded in 2022. Hence, the escalating demand for biologics is stimulating the expansion of the autoimmune monoclonal antibody market.

Which Firms Dominate The Autoimmune Monoclonal Antibody Market Segments?
Major companies operating in the autoimmune monoclonal antibody market are Johnson & Johnson, F. Hoffmann-La Roche Ltd, Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., UCB S.A., Genmab A/S, Zymeworks Inc., Xencor Inc., Immutep Limited, Cue Biopharma Inc., Santa Ana Bio Inc.

What Trends Are Driving Growth in The Autoimmune Monoclonal Antibody Market?
The foremost companies in the autoimmune monoclonal antibody market are concentrating on creating innovative solutions, including the development of biosimilars, to improve safety, efficacy, and quality. Biosimilar development consists of building highly similar, secure, and effective biological products to existing approved biologics. This is achieved using cutting-edge biotechnology, rigorous analytical testing, and clinical studies. These steps establish similar quality, efficacy, and safety for regulatory approval. For example, in February 2025, Biocon Biologics Limited, a biopharmaceutical organization from India, introduced YESINTEK, a biosimilar aimed at treating autoimmune diseases like Crohn's disease, ulcerative colitis, and psoriasis. It acts by targeting and suppressing the activity of interleukin-12 and interleukin-23, thus reducing inflammation and controlling the immune response. Yesintek assists with comprehensive disease management and enhances patient access to biologic therapies, by emulating the reference product, stelara.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/autoimmune-monoclonal-antibody-global-market-report

Which Is The Largest Region In The Autoimmune Monoclonal Antibody Market?
North America was the largest region in the autoimmune monoclonal antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the autoimmune monoclonal antibody market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Autoimmune Monoclonal Antibody Market?
2. What is the CAGR expected in the Autoimmune Monoclonal Antibody Market?
3. What Are the Key Innovations Transforming the Autoimmune Monoclonal Antibody Industry?
4. Which Region Is Leading the Autoimmune Monoclonal Antibody Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.